Recordati

REC

IT0003828271

Pharmaceuticals

Real-time Borsa Italiana Other stock markets 05:41:33 2026-02-13 am EST			5-day change	1st Jan Change
47.56 ^EUR	+0.34%		+0.76%	-2.02%

05:18am	DIARY - Italy to March 31	RE
Feb. 12	Barclays Upgrades Recordati to Equalweight Rating	MT

STRM.BIO, Inc. announces tranche update

Published on 01/07/2026 at 12:52 pm EST - Modified on 01/06/2026

S&P Capital IQ

RECORDATI

+0.34%

On January 7, 2026, the company announced that it has received $8,000,000 in in its first tranche. The transaction included participation from new investors Recordati Industria Chimica e Farmaceutica S.p.A., Blue Bay Capital Fund and returning investors, Boehringer Ingelheim, Delos Advisors Limited. The company intent to close this round by Q1 2026.

Latest news about Recordati

05:18am	DIARY - Italy to March 31	RE
Feb. 12	Barclays Upgrades Recordati to Equalweight Rating	MT
Feb. 12	Italy - Factors to watch on February 12	RE
Feb. 11	TIM and Italgas Push Higher, but the Mib Remains Bearish	AN
Feb. 10	Recordati Purchases Own Shares Worth Approximately EUR 3 Million	AN
Feb. 10	DIARY - Italy to March 31	RE
Feb. 03	Recordati Buys Back Over EUR3 Million in Own Shares	AN
Feb. 03	Italy - Factors to watch on February 3	RE
Feb. 02	Europe Expected to Open Lower, Gold Slide Continues	AN
Jan. 30	Mib Outperforms Europe Ahead of S&P, Campari Leads Gains	AN
Jan. 30	Markets Rise Amid Strong Euro and Earnings Season	AN
Jan. 30	Recordati and Moderna Sign Global Agreement on mRNA Therapy for Rare Disease	AN
Jan. 29	Moderna Collaborates With Recordati to Advance, Commercialize Investigational Therapy to Treat Metabolic Disorder	MT
Jan. 29	Recordati announces collaboration with Moderna for mRNA-3927	RE
Jan. 27	Recordati Purchases Approximately 77,600 Own Shares for EUR4 Million	AN
Jan. 20	Recordati Purchases 72,712 Own Shares for Over EUR3 Million	AN
Jan. 20	Mediobanca Downgrades Recordati to Neutral, Reduces PT	MT
Jan. 14	Recordati Industria Chimica e Farmaceutica S.p.A. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 11:15 AM
Jan. 12	Recordati Acquires 74,165 Own Ordinary Shares	AN
Jan. 07	STRM.BIO, Inc. announces tranche update	CI
Jan. 05	Recordati Buys Back 52,000 Own Shares for Over EUR2 Million	AN
Dec. 31	US FDA declines to approve Corcept's drug for rare hormonal disorder	RE
Dec. 23	Recordati Acquires 13,050 Own Shares for Approximately EUR570,000	AN
Dec. 18	Mixed European Markets, Central Banks in the Spotlight	AN
Dec. 17	Mixed European Markets Ahead of ECB Decision, Mib Turns Bullish	AN

Chart Recordati

Duration

Period

REC: Dynamic Chart

Company Profile

Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical and OTC products (64.4%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.; - medicines for rare diseases (35.6%). Net sales are distributed geographically as follows: Italy (14.3%), Europe (56.1%), America (20.4%), Asia and Oceania (6.7%) and Africa (2.5%).

Employees

4,539

Sector

Pharmaceuticals

Calendar

Feb. 18 - Q4 2025 Earnings Release (Projected)

More about the company